Real-time PCR assay for detection of fluoroquinolone resistance associated with grlA mutations in Staphylococcus aureus

被引:13
作者
Lapierre, P
Huletsky, A
Fortin, V
Picard, FJ
Roy, PH
Ouellette, M
Bergeron, MG
机构
[1] Univ Laval, CHUQ, Ctr Rech Infect, Ste Foy, PQ G1V 4G2, Canada
[2] Univ Laval, Fac Med, Div Microbiol, Ste Foy, PQ G1V 4G2, Canada
[3] Univ Laval, Fac Sci & Genie, Dept Biochem & Microbiol, Ste Foy, PQ G1V 4G2, Canada
关键词
D O I
10.1128/JCM.41.7.3246-3251.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Resistance to fluoroquinolones among clinical isolates of Staphylococcus aureus has become a clinical problem. Therefore, a rapid method to identify S. aureus and its susceptibility to fluoroquinolones could provide clinicians with a useful tool for the appropriate use of these antimicrobial agents in the health care settings. In this study, we developed a rapid real-time PCR assay for the detection of S. aureus and mutations at codons Ser-80 and Glu-84 of the grlA gene encoding the DNA topoisomerase IV, which are associated with decreased susceptibility to fluoroquinolones. The detection limit of the assay was 10 genome copies per reaction. The PCR assay was negative with DNA from all 26 non-S. aureus bacterial species tested. A total of 85 S. aureus isolates with various levels of fluoroquinolone resistance was tested with the PCR assay. The PCR assay correctly identified 100% of the S. aureus isolates tested compared to conventional culture methods. The correlation between the MICs of ciprofloxacin, levofloxacin, and gatifloxacin and the PCR results was 98.8%. The total time required for the identification of S. aureus and determination of its susceptibility to fluoroquinolones was about 45 min, including DNA extraction. This new rapid PCR assay represents a powerful method for the detection of S. aureus and its susceptibility to fluoroquinolones.
引用
收藏
页码:3246 / 3251
页数:6
相关论文
共 31 条
[1]  
ACAR JF, 1997, CLIN INFECT DIS S1, V24, P67
[2]   Thermodynamic basis of the enhanced specificity of structured DNA probes [J].
Bonnet, G ;
Tyagi, S ;
Libchaber, A ;
Kramer, FR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (11) :6171-6176
[3]   Survey of infections due to Staphylococcus species:: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Diekema, DJ ;
Pfaller, MA ;
Schmitz, FJ ;
Smayevsky, J ;
Bell, J ;
Jones, RN ;
Beach, M .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S114-S132
[4]   Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus [J].
Fukuda, H ;
Hori, S ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :1917-1922
[5]   Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus [J].
Gootz, TD ;
Zaniewski, RP ;
Haskell, SL ;
Kaczmarek, FS ;
Maurice, AE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1845-1855
[6]   Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC) [J].
Hannachi-M'Zali, F ;
Ambler, JE ;
Taylor, CF ;
Hawkey, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :649-655
[7]   In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections [J].
HoogkampKorstanje, JAA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :427-431
[8]   Fluoropuinolone resistance among Gram-positive cocci [J].
Hooper, DC .
LANCET INFECTIOUS DISEASES, 2002, 2 (09) :530-538
[9]   Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus [J].
Ince, D ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2755-2764
[10]   Rapid extraction from and direct identification in clinical samples of methicillin-resistant staphylococci using the PCR [J].
Jaffe, RI ;
Lane, JD ;
Albury, SV ;
Niemeyer, DM .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3407-3412